Scientists from the University of Lisbon have described how telomeres can establish the maximum damage that a cancer cell can suffer. Above this threshold, the cell would stop dividing and die. The damage comes from the transcription of the telomeres themselves of an RNA molecule called TERRA. When TERRA’s levels increase, the cell can no longer multiply. This mechanism occurs in ALT (alternative lengthening of telomeres) cells, which do not elongate their telomeres through telomerase. Read More
As therapeutics development in Alzheimer’s disease (AD) is broadening its search for therapeutic targets, one of the alternatives to amyloid-β, or at least to its direct targeting by monoclonal antibodies, that is coming into focus is triggering receptor expressed on myeloid cells 2 (TREM2). From a drug development standpoint, amyloid-β remains a mystery. Scientific evidence clearly suggests that amyloid misprocessing is an underlying factor in the development of AD, and it is certainly a reasonable hypothesis that reducing amyloid plaque should fight the disease. Read More
SBT-101 (Swanbio Therapeutics Inc.) is an adeno-associated virus serotype 9 (AAV9)-based gene therapy that delivers a functional copy of the ABCD1 gene and is under development for the treatment of adrenomyeloneuropathy (AMN). Read More
Therapeutic Solutions International Inc. has announced promising data on the use of Campbellcell for treatment of bipolar disorder by the company's suicide prevention-based spin-off Campbell Neurosciences Inc. Read More
The development of needle-free mucosal vaccines for SARS-CoV-2 would be advantageous, potentially reducing viral acquisition as well as transmission. Read More
Netris Pharma SAS has entered into a scientific collaboration agreement with Orano SA and the Centre Léon Bérard (CLB) to develop novel antibody-radio conjugates for the treatment of cancer. Read More
Researchers from Anacor Pharmaceuticals Inc. and Pfizer Inc. have published preclinical data for the novel benzoxaborole prodrug AN-15368, being developed for the treatment of Chagas disease. Read More
Korea University Research and Business Foundation (KURBF) has identified adamantyl derivatives acting as dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, Parkinson's disease, nonalcoholic steatohepatitis (NASH), rheumatoid arthritis, aortic valve stenosis and cerebrovascular and dermatological disorders. Read More
Biopharma Corp. has described triazolyl combretastatin derivatives reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19). Read More
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two devastating neurodegenerative diseases, with clinical, pathological and genetic overlap, without effective therapy. Read More
Tsd Life Sciences Co. Ltd. has discovered imidazopyridine derivatives acting as protein kinase inhibitors and reported to be useful for the treatment of cancer. Read More
F. Hoffmann-La Roche Ltd. has divulged pyrimidin-2-yl sulfonamide derivatives acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists reported to be useful for the treatment of obesity, Alzheimer's disease, Parkinson's disease, meningitis, encephalitis, ischemia, demyelinating diseases and schizophrenia. Read More
Emulate Inc. has launched a new adeno-associated virus (AAV) transduction application for the Liver-Chip that enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors in a validated, human-relevant model of the liver and get results in weeks. Read More
Medshine Discovery Inc. has patented gonadotropin-releasing hormone receptor (GnRHR) antagonists reported to be useful for the treatment of endometriosis and uterine fibroids. Read More
